PUBLISHER: The Business Research Company | PRODUCT CODE: 1951732
PUBLISHER: The Business Research Company | PRODUCT CODE: 1951732
Drug formulation refers to the process of combining multiple chemical and biological components, including the active pharmaceutical ingredient, to produce a finished medicinal product. It is used to modify and optimize drugs during the preclinical phase and early-stage research.
The primary dosage form types in drug formulation include oral, parenteral, topical, and inhalation formulations. Oral formulation involves the development and manufacturing of medicines intended for oral administration. These formulations are available in various forms such as tablets, capsules, injectables, sprays, suspensions, powders, and others, and are used to treat conditions including cardiovascular diseases, pain, diabetes, cancer, respiratory disorders, and others. They are utilized by a range of end users, including large pharmaceutical companies, small and medium-sized enterprises, and biotechnology companies.
Tariffs have influenced the drug formulation market by increasing the cost of imported active pharmaceutical ingredients (APIs), excipients, and specialized equipment. The impact is most pronounced in oral and parenteral formulation segments across regions like Asia-Pacific and Europe, which are key suppliers. This has prompted manufacturers to explore local sourcing, diversify suppliers, and optimize supply chains. Positive effects include incentivizing domestic production and boosting local biotech and pharmaceutical manufacturing capabilities, which could strengthen regional market resilience.
The drug formulation market research report is one of a series of new reports from The Business Research Company that provides drug formulation market statistics, including drug formulation industry global market size, regional shares, competitors with a drug formulation market share, detailed drug formulation market segments, market trends and opportunities, and any further data you may need to thrive in the drug formulation industry. This drug formulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The drug formulation market size has grown strongly in recent years. It will grow from $2045.31 billion in 2025 to $2221.54 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to growth in generic drug demand, rising prevalence of chronic diseases, advancements in pharmaceutical research, expansion of hospital and clinic networks, increasing investments in R&D.
The drug formulation market size is expected to see strong growth in the next few years. It will grow to $3196.24 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to emergence of gene and cell therapies, adoption of AI in drug design, development of novel excipients, increase in biologics and specialty drugs, expansion of emerging pharmaceutical markets. Major trends in the forecast period include personalized drug formulations, advanced drug delivery systems, biologics and biosimilars development, formulation stability and shelf-life optimization, regulatory compliance and quality assurance.
The growing adoption of personalized medicine is anticipated to drive the expansion of the drug formulation market in the coming years. Personalized medicine is an advanced healthcare strategy that customizes medical treatments and interventions according to the unique characteristics of each patient. It involves designing therapies based on individual patient factors, including genetics and biomarkers. This strategy requires the creation of customized drug formulations to enhance effectiveness and ensure patient safety. Its influence includes the demand for individualized treatment approaches, formulations that incorporate genomic data, improved drug responses, and targeted therapies for rare conditions. For example, in 2023, according to the Personalized Medicine Coalition (PMC), a US-based non-profit organization, personalized medicines represented about 38 percent of all newly approved therapeutic molecular entities, increasing from 34 percent in 2022. Consequently, the rising adoption of personalized medicine is fueling the growth of the drug formulation market.
Leading companies in the drug formulation market are focusing on the development of new fixed-dose combination drugs for type 2 diabetes to strengthen their competitive position. A Fixed Dose Combination (FDC) is a pharmaceutical formulation that includes two or more active ingredients combined in a predetermined ratio within a single dosage form. For example, in October 2023, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, introduced its first triple-drug fixed-dose combination under the brand name Zita DM. The formulation comprises the DPP4 inhibitor Teneligliptin (20 mg), the SGLT2 inhibitor Dapagliflozin (10 mg), and Metformin SR (500 mg/1000 mg) in fixed doses. It is prescribed as a once-daily medication to enhance glycemic control in patients with type 2 diabetes.
In May 2025, Roquette, a France-based supplier of plant-based ingredients and pharmaceutical excipients, acquired IFF Pharma Solutions for an undisclosed sum. Through this acquisition, Roquette seeks to reinforce its presence in the global pharmaceutical excipients market and expand its drug delivery capabilities by incorporating IFF's innovation portfolio and technical know-how. IFF Pharma Solutions is a US-based company that designs and produces pharmaceutical excipients and specialized solutions for oral dosage forms.
Major companies operating in the drug formulation market are AstraZeneca PLC, The Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., C.H. Boehringer Sohn AG & Co. KG, F. Hoffmann-La Roche AG, Johnson & Johnson, Bayer AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, Novo Nordisk A/S, Amgen Inc., Viatris Inc., Sandoz International GmbH, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Limited, Torrent Pharmaceuticals Limited, Jubilant Life Sciences Limited, Cadila Healthcare Limited, Glenmark Pharmaceuticals Ltd., Wockhardt Ltd., Hikma Pharmaceuticals plc
North America was the largest region in the drug formulation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the drug formulation market report during the forecast period. The regions covered in the drug formulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the drug formulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The drug formulation market includes revenues earned by entities by providing formulation optimization, process optimization, and scale-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Drug Formulation Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses drug formulation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for drug formulation ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug formulation market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.